Zoekresultaten

  1. Personen Meer...

  2. 22 jun.

    slightly frustrating see it rise & fall. Three major pipeline streams here with hRPC, Exosomes & CTX through the Fosun pharma deal. Absolutely no reason for me to sell. I hold 1% of the company. Potentially Octopus selling causing weakness. Griffiths keeps adding more ✅

    12 vind-ik-leuks
  3. 19 uur geleden

    Not me 😁 In the last few months I have taken advantage of dips in all of my major long term conviction plays

    What investors say when stocks are going up: "I would love to buy more of what I own lower." When stocks go lower: "No, I'm good." 😂😄
    1 retweet 13 vind-ik-leuks
  4. 23 jun.

    Fantastic 👇

    Kite partners with Shoreline Biosciences for their expertise in induced pluripotent stem cells (iPSC). The deal is worth up to $2.3Billion These are the kind of deals could be signing soon for their iPSC platform.
    1 retweet 3 vind-ik-leuks
  5. 23 jun.

    Kite partners with Shoreline Biosciences for their expertise in induced pluripotent stem cells (iPSC). The deal is worth up to $2.3Billion These are the kind of deals could be signing soon for their iPSC platform.

    1 antwoord 1 retweet 8 vind-ik-leuks
  6. 19 jun.
    Als antwoord op

    Totally agree mate Currently 97% of my Capital is locked in / My portfolio is currently at all time highs and my biggest position 4D hasn’t even started moving yet 🔥📈

    6 retweets 19 vind-ik-leuks
  7. 24 jun.

    V quite week I must say💤 Nevertheless very happy with my holdings in Looking forward to seeing how the next 6 months plays out😎 All 🤞should be in a materially different place over that time span Game changing new on the horizon

    4 antwoorden 12 vind-ik-leuks
  8. 20 jun.

    “Just as gene therapy went from being a fantasy with little practical value to becoming a major area of treatment,” stem cells are “within a few years of reaching the medical mainstream.”

    2 antwoorden 3 retweets 8 vind-ik-leuks
    Deze collectie tonen
    Deze collectie tonen
  9. 20 jun.

    'British micro-cap biotech ReNeuron (Aim: RENE) is developing adult stem-cell treatments for several conditions. It is currently carrying out clinical trials for patients with retinal degeneration and those recovering from the effects of having a stroke.

    1 antwoord 2 retweets 2 vind-ik-leuks
    Deze collectie tonen
    Deze collectie tonen
  10. 21 jun.
    Als antwoord op

    That is exactly why it is my 2nd largest holding after pharma.

    1 antwoord 1 retweet 5 vind-ik-leuks
  11. 21 jun.
    Als antwoord op

    I'm no longer in , Sid. Had too many holdings and cut it. Traded the recent bounce but it's on the watchlist for now.

    1 antwoord 1 vind-ik-leuk
  12. 20 jun.

    💰All have 10+ BAGGING POTENTIAL in the next 2 years💰

    "Stand by your stocks as long as the fundamental story of the company hasn’t changed” – Peter Lynch
    6 retweets 21 vind-ik-leuks
  13. 21 jun.

    Now playing Save Your Love (For #1) on by & !

  14. 20 jun.

    ReNeuron has also developed its own induced pluripotent stem cell (iPSC) platform for research purposes and is seeking collaborations with other drug and biotech companies.

    2 antwoorden 1 retweet 3 vind-ik-leuks
    Deze collectie tonen
    Deze collectie tonen
  15. 6 uur geleden

    Otis : I'm lost - Album "Vaughan and violins" - Sarah Vaughan, voix / Orch Studio / Q.Jones .

  16. 23 jun.

    🧬 ⏰Proof of concept data expected IMMINENTLY regarding collab with INDUSTRY LEADING pharma 's human Neural (🧠) Stem Cell delivery vehicle📦 delivering INDUSTRY LEADING partners proprietary Gene Therapy 🧬 🔥FULLY FUNDED BY INDUSTRY LEADING PARTNER🔥

    1 antwoord 2 retweets 3 vind-ik-leuks
    Deze collectie tonen
    Deze collectie tonen
  17. 23 jun.

    anything is possible. I’ve taken the risk.

    Kite partners with Shoreline Biosciences for their expertise in induced pluripotent stem cells (iPSC). The deal is worth up to $2.3Billion These are the kind of deals could be signing soon for their iPSC platform.
    1 antwoord 1 retweet 2 vind-ik-leuks
    Deze collectie tonen
    Deze collectie tonen
  18. 22 jun.

    Most precipitous spell this yr. It'll pass 🤞 Nervousness in the biotech/pharma arena. Back to where I was early April! Holding firmly: , , , , , , , , , , , , , , , , , , , , GLA!

    1 antwoord 3 vind-ik-leuks
  19. 20 jun.

    Like other small biotech firms in this area, it is not making any money, so it is an extremely risky investment – although the rewards could be huge if any of its treatments show positive results from their clinical trials.'

    1 antwoord 2 vind-ik-leuks
    Deze collectie tonen
    Deze collectie tonen
  20. 25 jun.
    Als antwoord op

    Cell therapy. E.g. .

    1 retweet 1 vind-ik-leuk
  21. 23 jun.
    Als antwoord op

    🧬 PEOPLE ARE SLEEPING ON potential😴💤 Another iPSC deal worth 💰$2.3BILLION💰 this week Kite (a company) licencing Shoreline Bio's Technology

    Kite partners with Shoreline Biosciences for their expertise in induced pluripotent stem cells (iPSC). The deal is worth up to $2.3Billion These are the kind of deals could be signing soon for their iPSC platform.
    1 antwoord 1 retweet 3 vind-ik-leuks

Geen resultaten.

Het laden lijkt wat langer te duren.

Twitter is mogelijk overbelast of ondervindt een tijdelijke onderbreking. Probeer het opnieuw of bekijk de Twitter-status voor meer informatie.